Zurück
Befasse mich nun schon anderthalb jahre mit diesem Wert und wie ich meine ziemlich intensiv. 10000 % sind vielleicht möglich vielleicht auch 20000 % aber wo bitte befasst sich geron mit gentherapie?
gruss meislo
gruss meislo
Top-News
STEMCELLS 889118 expoldiert gerade !
Beiträge:
36
Zugriffe: 6.581 / Heute: 15
Zugriffe: 6.581 / Heute: 15
|
| ||||||||||||||
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +63,87%
Xtrackers S&P 500 2x Leveraged Daily Swap UCITS ETF 1C
Perf. 12M: +48,73%
Xtrackers MSCI USA Information Technology UCITS ETF 1D
Perf. 12M: +38,34%
Xtrackers MSCI World Information Technology UCITS ETF 1C
Perf. 12M: +37,13%
Xtrackers MSCI USA Banks UCITS ETF 1D
Perf. 12M: +36,83%
mit CellGenesys. Genveränderte viren auf telomerasebasis.
Hier ist CellGenesys der operator und geron hat nur die rechte an der telomerase vermarktet. Nach meinem verständnis hat dies aber wenig mit gentherapie im bunde.
Cancer Programs : Oncolytic Virus
Another of our anti-cancer therapeutic strategies utilizes viruses that have been manipulated or engineered to have oncolytic, or cancer-killing, properties, enabling them to selectively target and destroy cancer cells which express telomerase. We have cloned the promoter region of the telomerase gene and employ it to switch on genes required for the virus to replicate within the cancer cell. Our data indicate that when tumor cells are infected with the virus, the virus multiplies or replicates within the cancer cells and causes the rupture and death of the tumor cells. When these same engineered viruses infect normal somatic cells, there is no killing effect and the virus dissipates. This selective lytic effect on cancer has been demonstrated in vitro in seven different tumor types: prostate, liver, lung, pancreatic, colorectal, breast and ovarian cancers. These in vitro results have been extended to animal models of liver and prostate cancer with similar effects against the animals’ tumors while sparing normal cells.
We granted a non-exclusive license to Genetic Therapy, Inc. (GTI), a subsidiary of Novartis AG, to use our telomerase promoter technology to develop an oncolytic virus product. In 2003, GTI's oncolytic virus assets and our license to GTI were acquired by Cell Genesys, which was already active in the field of oncolytic viruses, and is continuing the development of oncolytic viruses using the telomerase promoter.
gruss meislo
Hier ist CellGenesys der operator und geron hat nur die rechte an der telomerase vermarktet. Nach meinem verständnis hat dies aber wenig mit gentherapie im bunde.
Cancer Programs : Oncolytic Virus
Another of our anti-cancer therapeutic strategies utilizes viruses that have been manipulated or engineered to have oncolytic, or cancer-killing, properties, enabling them to selectively target and destroy cancer cells which express telomerase. We have cloned the promoter region of the telomerase gene and employ it to switch on genes required for the virus to replicate within the cancer cell. Our data indicate that when tumor cells are infected with the virus, the virus multiplies or replicates within the cancer cells and causes the rupture and death of the tumor cells. When these same engineered viruses infect normal somatic cells, there is no killing effect and the virus dissipates. This selective lytic effect on cancer has been demonstrated in vitro in seven different tumor types: prostate, liver, lung, pancreatic, colorectal, breast and ovarian cancers. These in vitro results have been extended to animal models of liver and prostate cancer with similar effects against the animals’ tumors while sparing normal cells.
We granted a non-exclusive license to Genetic Therapy, Inc. (GTI), a subsidiary of Novartis AG, to use our telomerase promoter technology to develop an oncolytic virus product. In 2003, GTI's oncolytic virus assets and our license to GTI were acquired by Cell Genesys, which was already active in the field of oncolytic viruses, and is continuing the development of oncolytic viruses using the telomerase promoter.
gruss meislo
www.forbes.com/2004/11/01/cz_sg_1101soapbox.html
California's Stem Cell Follies
Scott Gottlieb, Forbes/Gottlieb Medical Technology Investor, 11.01.04, 2:30 PM ET
Click here to profit from our free Monday morning e-mail dispatch, Forbes Newsletters' Stock of the Week.
On Wall Street, investment bankers disdainfully refer to two types of investors, "smart money" and "dumb money." In their snooty lexicon, smart money belongs to elite investors that run hedge funds and venture capital catering to the wealthy. Smart money benefits from growing trade in pricey insider information that doesn't flow to regular people. Dumb money belongs to ordinary investors shut out of this elite trafficking. After Tuesday, all of the dumb money may belong to California voters.
Besides selecting a president on Tuesday, Californians will be voting on the celebrated Proposition 71, a state initiative to fund stem-cell research that would eventually cost Californians $6 billion--$3 billion in bonds and $3 billion in interest payments for 10 years. If the prop passes, cash-strapped California taxpayers will be spending their money on a handful of second-rate biotech companies that the smart venture capital money housed around San Francisco's famed Bay Area already passed on. To the smart money, these companies had poor prospects and, in many cases, shoddy or highly speculative science.
That's not to say Wall Street's elite investors didn't make their own investments in stem cell research. But after years of delays, disappointments, and dead ends, most of the venture capital that once flowed into these ventures is slowing down and awaiting better science to come out of institutions and academic research.
Special Offer: For monthly investment insights into the world of biotech, pharmaceutical and healthcare policy subscribe to our new Forbes/Gottlieb Medical Technology Investor. Click here for more information.
Stem cells are the primordial goop of the human body, human cells that have not yet been differentiated into, say, bone, blood or brain cells. For medical researchers, stem cells represent a mother lode of possible new treatments for diabetes, heart disease, Parkinson's, Alzheimer's, and more. Capable of differentiating into the full spectrum of other cell types--from a new liver cell to a new neuron--they could be ideal for repairing or replacing diseased organs.
The current furor over stem-cell research is not over their eventual usefulness, but their source: Should researchers use federal money to harvest stem cells from aborted or discarded human embryos? Or should they be restricted to adult stem cells, found in fat, bone, and the brain? Foes of embryonic stem cell research object mostly to the specter of human fetuses becoming incubators to be aborted and harvested simply for their cell products.
In August of 2001, President Bush split the difference between the two political sides by limiting federal funding for stem cell research to lines of embryonic stem cells that already existed. Under the President's policy, no new fetuses would be harvested for their stem cells.
Of course, the limits on federal funding put no restrictions on what the private sector can do. All through the late 1990s investors cited uncertainty over what the government's policy would be as a principal reason for shunning investments in private companies doing stem cell research. They feared an outright government ban on private research. With that not in the cards, one would expect the pace of development to have quickened after the President's policy was unveiled.
Special Offer: Less than a month ago, Forbes Wireless Stock Watch recommended subscribers buy Smith Micro Software at $3.67. Today it trades for $6.00, a gain of over 60%! Don't miss the wireless revolution. Click here to find out which hidden gems FWSW is buying today.
Yet private investment remains tepid, even three years after the President's policy took all political uncertainty off the table. In fact, from 1994 to 2004, only about $300 million in private venture capital money has flowed into the handful of established U.S. biotechnology companies doing research into embryonic and adult stem cells (see chart below). That's out of about $30 billion in venture capital money that flowed into biotechnology over that time. And most of the little money that made its way to these companies was spent on those that did research with adult, not embryonic, stem cells.
Enter the state of California. Now, amidst record state budget deficits, California is prepared to pump $8 billion into a handful of second-rate biotechnology companies on whose scientific fortunes private investors have already decided to largely pass. The persistent enthusiasm for stem cells has outpaced their scientific legitimacy because the issue has been caught up in electoral politics, with Democrats sensing a wedge issue with which to divide voters. Nobody doubts stem cells may one day yield useful medical treatments, it is just not apparent that messing around with embryonic stem cells and all their associated ethical baggage is all that necessary. Many scientists believe everything that can be done with embryonic stem cells can also be done with adult stem cells, harvested from peoples' blood and bone marrow and even their fat.
One place this can be seen is diabetes research. While some studies have claimed progress in getting embryonic stem cells to differentiate into insulin-producing cells in culture, those claims are called into doubt in a recent study in the journal Diabetologia. Researchers from the University of Calgary found that the insulin-producing cells derived from embryonic stem cells are not the "beta cells" needed to reverse diabetes. While the cells were coaxed to produce some insulin, they did not do so in response to changes in sugar levels, and when they were transplanted into mice they formed tumors.
Special Offer: Don't miss out on the next Taser! With homeland security and counterterrorism spending on the rise, security stocks are the new growth stocks. For a list of stocks to buy now, click here for the latest issue of Spear's Security Industry Analyst.
By contrast, the most promising new treatment for juvenile diabetes in recent years didn't involve stem cells but pancreas cells harvested from donors. It's called the Edmonton protocol. And of the roughly 250 patients who have received the newest version of the transplant, more than 80% have been free from insulin shots or insulin pumps for more than a year.
There have also been some recent advances using adult stem cells to treat diabetes. Researchers in Canada have shown that transplanted adult stem cells from bone marrow can cause pancreatic tissue to repair itself, restoring normal insulin production and reversing symptoms of diabetes. The team has reversed diabetes in mice and hopes to move to human trials. And researchers at Massachusetts General Hospital have used adult cells from the spleen to regenerate insulin-producing cells and cure diabetes in mice. Essentially the spleen cells "retrain" the body's immune system to stop attacking its own insulin-producing pancreas cells, and new cells then naturally regenerate.
But politicians, including California's Democratic State Legislature, sense a wedge. They are preying on peoples' desire for cures to debilitating diseases. They are willing to waste $6 billion of their taxpayers' money to make their point.
Don't expect the California money to change the fortunes of science. There's plenty of precedent for this kind of direct investment by a government authority. The trade publication BioCentury recently chronicled investments that Germany made in its homegrown biotechnology industry. The German government invested millions into dozens of second-tier biotechnology companies that ultimately shrank, folded or limped along as small research projects.
If the embryonic stem cells ever appear to have clear advantage over adult cells, there's plenty of money to fund their development. In addition to the federal funds that President Bush has already authorized, private foundations and especially "smart money" on Wall Street stand ready to chase the opportunity. The only question that remains is how much more "dumb money" will be wasted before we settle the issue. On Tuesday, California voters get a chance to decide.
Investments In US Companies Conducting Embryonic And Adult Stem Cell Research: Selected Venture Capital Rounds, 1994-2004
Company Amount of VC Invested (millions)
1994
Geron Corp (nasdaq: GERN - news - people ) $12.6
1995
Aastrom Biosciences Inc (nasdaq: ASTM - news - people ) $10.0
1996
Geron Corp $11.7
Osiris $10.0
BioTransplant Inc (nasdaq: BTRN - news - people ) $7.0
1999
BresaGen $7.6
ViaCell $6.0
2000
Geron $25.0
ViaCell $59.0
NeuralStem Biopharmaceuticals $5.5
NeuroNova AB $3.45
VistaGen Inc $1.0
Cythera Inc. $2.0
2001
ViaCell $15.0
Layton Biosciences $11.0
MorphoGen Pharmaceuticals $8.5
StemCells Inc (nasdaq: STEM - news - people ) $7.0
StemSource $2.5
Nephros Therapeutics Inc. $8.7
2002
ViaCell $1.5
StemCells Inc $1.1
Neuronyx Inc undisclosed
Nephros Therapeutics Inc. $17.0
2003
ViaCell $41.5
Geron $18.4
StemCells Inc $8.15
Cythera Inc. $2.0
Source: BioCentury, American Enterprise Institute. Companies listed may have merged or closed operations over the time period covered.
Total Venture Capital Investment In Biotech By Year
1994 $526,645,000
1995 $564,705,000
1996 $934,355,174
1997 $1,270,235,018
1998 $1,476,808,860
1999 $1,957,285,292
2000 $5,112,286,305
2001 $4,694,772,847
2002 $3,955,809,272
2003 $4,012,864,340
2004 $4,486,772,956
Source: BioCentury
Excerpted from the Oct. 18 issue of Dow Theory Forecasts. Click here for more information and to subscribe to Dow Theory Forecasts or click here for more information and to subscribe to Upside.
Scott Gottlieb is a physician and Fellow at the American Enterprise Institute. Until October, he was Senior Advisor to the head of the Medicare and Medicaid Program, Dr. Mark McClellan. Previously, Dr. Gottlieb was Director of Medical Policy Development at the Food and Drug Administration. For more information and to subscribe to the Forbes/Gottlieb Medical Technology Report, click here.
California's Stem Cell Follies
Scott Gottlieb, Forbes/Gottlieb Medical Technology Investor, 11.01.04, 2:30 PM ET
Click here to profit from our free Monday morning e-mail dispatch, Forbes Newsletters' Stock of the Week.
On Wall Street, investment bankers disdainfully refer to two types of investors, "smart money" and "dumb money." In their snooty lexicon, smart money belongs to elite investors that run hedge funds and venture capital catering to the wealthy. Smart money benefits from growing trade in pricey insider information that doesn't flow to regular people. Dumb money belongs to ordinary investors shut out of this elite trafficking. After Tuesday, all of the dumb money may belong to California voters.
Besides selecting a president on Tuesday, Californians will be voting on the celebrated Proposition 71, a state initiative to fund stem-cell research that would eventually cost Californians $6 billion--$3 billion in bonds and $3 billion in interest payments for 10 years. If the prop passes, cash-strapped California taxpayers will be spending their money on a handful of second-rate biotech companies that the smart venture capital money housed around San Francisco's famed Bay Area already passed on. To the smart money, these companies had poor prospects and, in many cases, shoddy or highly speculative science.
That's not to say Wall Street's elite investors didn't make their own investments in stem cell research. But after years of delays, disappointments, and dead ends, most of the venture capital that once flowed into these ventures is slowing down and awaiting better science to come out of institutions and academic research.
Special Offer: For monthly investment insights into the world of biotech, pharmaceutical and healthcare policy subscribe to our new Forbes/Gottlieb Medical Technology Investor. Click here for more information.
Stem cells are the primordial goop of the human body, human cells that have not yet been differentiated into, say, bone, blood or brain cells. For medical researchers, stem cells represent a mother lode of possible new treatments for diabetes, heart disease, Parkinson's, Alzheimer's, and more. Capable of differentiating into the full spectrum of other cell types--from a new liver cell to a new neuron--they could be ideal for repairing or replacing diseased organs.
The current furor over stem-cell research is not over their eventual usefulness, but their source: Should researchers use federal money to harvest stem cells from aborted or discarded human embryos? Or should they be restricted to adult stem cells, found in fat, bone, and the brain? Foes of embryonic stem cell research object mostly to the specter of human fetuses becoming incubators to be aborted and harvested simply for their cell products.
In August of 2001, President Bush split the difference between the two political sides by limiting federal funding for stem cell research to lines of embryonic stem cells that already existed. Under the President's policy, no new fetuses would be harvested for their stem cells.
Of course, the limits on federal funding put no restrictions on what the private sector can do. All through the late 1990s investors cited uncertainty over what the government's policy would be as a principal reason for shunning investments in private companies doing stem cell research. They feared an outright government ban on private research. With that not in the cards, one would expect the pace of development to have quickened after the President's policy was unveiled.
Special Offer: Less than a month ago, Forbes Wireless Stock Watch recommended subscribers buy Smith Micro Software at $3.67. Today it trades for $6.00, a gain of over 60%! Don't miss the wireless revolution. Click here to find out which hidden gems FWSW is buying today.
Yet private investment remains tepid, even three years after the President's policy took all political uncertainty off the table. In fact, from 1994 to 2004, only about $300 million in private venture capital money has flowed into the handful of established U.S. biotechnology companies doing research into embryonic and adult stem cells (see chart below). That's out of about $30 billion in venture capital money that flowed into biotechnology over that time. And most of the little money that made its way to these companies was spent on those that did research with adult, not embryonic, stem cells.
Enter the state of California. Now, amidst record state budget deficits, California is prepared to pump $8 billion into a handful of second-rate biotechnology companies on whose scientific fortunes private investors have already decided to largely pass. The persistent enthusiasm for stem cells has outpaced their scientific legitimacy because the issue has been caught up in electoral politics, with Democrats sensing a wedge issue with which to divide voters. Nobody doubts stem cells may one day yield useful medical treatments, it is just not apparent that messing around with embryonic stem cells and all their associated ethical baggage is all that necessary. Many scientists believe everything that can be done with embryonic stem cells can also be done with adult stem cells, harvested from peoples' blood and bone marrow and even their fat.
One place this can be seen is diabetes research. While some studies have claimed progress in getting embryonic stem cells to differentiate into insulin-producing cells in culture, those claims are called into doubt in a recent study in the journal Diabetologia. Researchers from the University of Calgary found that the insulin-producing cells derived from embryonic stem cells are not the "beta cells" needed to reverse diabetes. While the cells were coaxed to produce some insulin, they did not do so in response to changes in sugar levels, and when they were transplanted into mice they formed tumors.
Special Offer: Don't miss out on the next Taser! With homeland security and counterterrorism spending on the rise, security stocks are the new growth stocks. For a list of stocks to buy now, click here for the latest issue of Spear's Security Industry Analyst.
By contrast, the most promising new treatment for juvenile diabetes in recent years didn't involve stem cells but pancreas cells harvested from donors. It's called the Edmonton protocol. And of the roughly 250 patients who have received the newest version of the transplant, more than 80% have been free from insulin shots or insulin pumps for more than a year.
There have also been some recent advances using adult stem cells to treat diabetes. Researchers in Canada have shown that transplanted adult stem cells from bone marrow can cause pancreatic tissue to repair itself, restoring normal insulin production and reversing symptoms of diabetes. The team has reversed diabetes in mice and hopes to move to human trials. And researchers at Massachusetts General Hospital have used adult cells from the spleen to regenerate insulin-producing cells and cure diabetes in mice. Essentially the spleen cells "retrain" the body's immune system to stop attacking its own insulin-producing pancreas cells, and new cells then naturally regenerate.
But politicians, including California's Democratic State Legislature, sense a wedge. They are preying on peoples' desire for cures to debilitating diseases. They are willing to waste $6 billion of their taxpayers' money to make their point.
Don't expect the California money to change the fortunes of science. There's plenty of precedent for this kind of direct investment by a government authority. The trade publication BioCentury recently chronicled investments that Germany made in its homegrown biotechnology industry. The German government invested millions into dozens of second-tier biotechnology companies that ultimately shrank, folded or limped along as small research projects.
If the embryonic stem cells ever appear to have clear advantage over adult cells, there's plenty of money to fund their development. In addition to the federal funds that President Bush has already authorized, private foundations and especially "smart money" on Wall Street stand ready to chase the opportunity. The only question that remains is how much more "dumb money" will be wasted before we settle the issue. On Tuesday, California voters get a chance to decide.
Investments In US Companies Conducting Embryonic And Adult Stem Cell Research: Selected Venture Capital Rounds, 1994-2004
Company Amount of VC Invested (millions)
1994
Geron Corp (nasdaq: GERN - news - people ) $12.6
1995
Aastrom Biosciences Inc (nasdaq: ASTM - news - people ) $10.0
1996
Geron Corp $11.7
Osiris $10.0
BioTransplant Inc (nasdaq: BTRN - news - people ) $7.0
1999
BresaGen $7.6
ViaCell $6.0
2000
Geron $25.0
ViaCell $59.0
NeuralStem Biopharmaceuticals $5.5
NeuroNova AB $3.45
VistaGen Inc $1.0
Cythera Inc. $2.0
2001
ViaCell $15.0
Layton Biosciences $11.0
MorphoGen Pharmaceuticals $8.5
StemCells Inc (nasdaq: STEM - news - people ) $7.0
StemSource $2.5
Nephros Therapeutics Inc. $8.7
2002
ViaCell $1.5
StemCells Inc $1.1
Neuronyx Inc undisclosed
Nephros Therapeutics Inc. $17.0
2003
ViaCell $41.5
Geron $18.4
StemCells Inc $8.15
Cythera Inc. $2.0
Source: BioCentury, American Enterprise Institute. Companies listed may have merged or closed operations over the time period covered.
Total Venture Capital Investment In Biotech By Year
1994 $526,645,000
1995 $564,705,000
1996 $934,355,174
1997 $1,270,235,018
1998 $1,476,808,860
1999 $1,957,285,292
2000 $5,112,286,305
2001 $4,694,772,847
2002 $3,955,809,272
2003 $4,012,864,340
2004 $4,486,772,956
Source: BioCentury
Excerpted from the Oct. 18 issue of Dow Theory Forecasts. Click here for more information and to subscribe to Dow Theory Forecasts or click here for more information and to subscribe to Upside.
Scott Gottlieb is a physician and Fellow at the American Enterprise Institute. Until October, he was Senior Advisor to the head of the Medicare and Medicaid Program, Dr. Mark McClellan. Previously, Dr. Gottlieb was Director of Medical Policy Development at the Food and Drug Administration. For more information and to subscribe to the Forbes/Gottlieb Medical Technology Report, click here.
Stem Cells: Embryonic Vs. Umbilical Cord Blood
Matthew Herper, 11.01.04, 2:55 PM ET
NEW YORK - The death of Christopher Reeve and the upcoming election have reignited the national debate on embryonic stem cells.
These cells have vast potential because they could, in theory, be used to replace any damaged tissue in the body, curing all sorts of diseases. But the gulf between what might be done someday and what can be done now is huge. George W. Bush is the first president to allow federally funded research on these cells. But based on his 2001 decision to fund the research, only 64 lines of those cells can be used by government-funded scientists. Of those cell lines, it is estimated that, at most, 22 are usable.
Here, we contrast embryonic stem cells with another variety, those stem cells derived from umbilical cord blood. The comparison gives an idea of how powerful these cell types are and also the great amount of research that still needs to be done. Legislation currently before Congress would allocate more federal money for doing research on these cells. It would also provide for establishing a national bank of umbilical cord blood, which might provide 80% of cancer patients in need of bone marrow transplants with stem cells, as compared with 25% today.
Irving Weissman, a leading stem cell biologist at Stanford University and founder of StemCells (nasdaq: STEM - news - people ), says not to view embryonic stem cells solely as therapies themselves. Given the potential they open up to study genetic diseases, they could be the source of a great deal of drug research over the next 40 years--if the research is allowed to continue .
" This is the largest potential of this technology," Weissman says, " and it would be stupid to ignore this fact."
Matthew Herper, 11.01.04, 2:55 PM ET
NEW YORK - The death of Christopher Reeve and the upcoming election have reignited the national debate on embryonic stem cells.
These cells have vast potential because they could, in theory, be used to replace any damaged tissue in the body, curing all sorts of diseases. But the gulf between what might be done someday and what can be done now is huge. George W. Bush is the first president to allow federally funded research on these cells. But based on his 2001 decision to fund the research, only 64 lines of those cells can be used by government-funded scientists. Of those cell lines, it is estimated that, at most, 22 are usable.
Here, we contrast embryonic stem cells with another variety, those stem cells derived from umbilical cord blood. The comparison gives an idea of how powerful these cell types are and also the great amount of research that still needs to be done. Legislation currently before Congress would allocate more federal money for doing research on these cells. It would also provide for establishing a national bank of umbilical cord blood, which might provide 80% of cancer patients in need of bone marrow transplants with stem cells, as compared with 25% today.
Irving Weissman, a leading stem cell biologist at Stanford University and founder of StemCells (nasdaq: STEM - news - people ), says not to view embryonic stem cells solely as therapies themselves. Given the potential they open up to study genetic diseases, they could be the source of a great deal of drug research over the next 40 years--if the research is allowed to continue .
" This is the largest potential of this technology," Weissman says, " and it would be stupid to ignore this fact."
After Hours
Time (ET) After Hours
Price After Hours
Share Volume
17.14 $ 4.27 700
17.14 $ 4.28 200
17.14 $ 4.27 1400
17.14 $ 4.28 250
17.14 $ 4.28 250
17.14 $ 4.28 500
17.14 $ 4.32 100
17.14 $ 4.28 2500
17.14 $ 4.27 1750
17.13 $ 4.27 100
17.13 $ 4.32 100
17.12 $ 4.27 750
17.11 $ 4.25 500
17.11 $ 4.23 100
17.10 $ 4.26 600
17.09 $ 4.23 5000
17.09 $ 4.23 1300
17.09 $ 4.23 300
17.08 $ 4.24 5000
17.08 $ 4.24 900
17.08 $ 4.23 125
17.07 $ 4.23 4875
17.07 $ 4.22 700
17.07 $ 4.32 100
17.07 $ 4.20 1900
17.07 $ 4.20 3100
17.07 $ 4.23 1000
17.06 $ 4.20 200
17.06 $ 4.20 1700
17.06 $ 4.19 3000
17.06 $ 4.20 700
17.06 $ 4.19 500
17.06 $ 4.19 500
17.05 $ 4.20 2700
17.05 $ 4.20 1000
17.05 $ 4.22 300
17.05 $ 4.22 300
17.05 $ 4.22 700
17.05 $ 4.22 200
17.04 $ 4.23 500
17.04 $ 4.23 1000
17.04 $ 4.24 1000
17.04 $ 4.24 100
17.04 $ 4.24 200
17.04 $ 4.24 1600
17.04 $ 4.25 100
17.04 $ 4.24 100
17.04 $ 4.25 100
17.04 $ 4.24 100
17.04 $ 4.25 100
In der Zeit zwischen 16:00 - 17:00 Uhr amerikanischer Zeit, lag Steamclls schon über 4,30 US$ ! Nach einer kleinen Abverkaufsphase konnte Stemcells aktuell wieder bis auf 4,28 US Dollar anziehen. ( hatte gerade aktuallisiert )
Also, neute Nacht sollte es wohl eher in Richtung 4,30 als 4,20 US$ gehen.
Morgen werden wir dann schön die 4,52 - 4,90 testen und hoffentlich hoch schließen.
Am Mittwoch ist sie geschaffen, die Basic für die Super-Hype-Ralley, oder für den Absturz.
Mittwoch wäre somit ein nicht schlechter Tag die Gewinne bei Steamcells ein zu streichen. Dabei bleibt nur die große Chance, bei positivem Ausgang der Befragung, das Stemcells erst richtig anfangen wird zu knallen ! Das würde dann heißen, das Stemcells die ganze Woche durch laufen wird und evtl. bis nächste Woche Dienstag anhalten.
Was meint Ihr ? Welches Kurspotenzial sehr Ihr, bei einer richtig heißen Ralley ohne Limit. Da wird in USA gezockt, was nur geht ! Je höher umso besser für uns ! :-)
Morgen geht die Party weiter ! Gruß Euer Byblos
Time (ET) After Hours
Price After Hours
Share Volume
17.14 $ 4.27 700
17.14 $ 4.28 200
17.14 $ 4.27 1400
17.14 $ 4.28 250
17.14 $ 4.28 250
17.14 $ 4.28 500
17.14 $ 4.32 100
17.14 $ 4.28 2500
17.14 $ 4.27 1750
17.13 $ 4.27 100
17.13 $ 4.32 100
17.12 $ 4.27 750
17.11 $ 4.25 500
17.11 $ 4.23 100
17.10 $ 4.26 600
17.09 $ 4.23 5000
17.09 $ 4.23 1300
17.09 $ 4.23 300
17.08 $ 4.24 5000
17.08 $ 4.24 900
17.08 $ 4.23 125
17.07 $ 4.23 4875
17.07 $ 4.22 700
17.07 $ 4.32 100
17.07 $ 4.20 1900
17.07 $ 4.20 3100
17.07 $ 4.23 1000
17.06 $ 4.20 200
17.06 $ 4.20 1700
17.06 $ 4.19 3000
17.06 $ 4.20 700
17.06 $ 4.19 500
17.06 $ 4.19 500
17.05 $ 4.20 2700
17.05 $ 4.20 1000
17.05 $ 4.22 300
17.05 $ 4.22 300
17.05 $ 4.22 700
17.05 $ 4.22 200
17.04 $ 4.23 500
17.04 $ 4.23 1000
17.04 $ 4.24 1000
17.04 $ 4.24 100
17.04 $ 4.24 200
17.04 $ 4.24 1600
17.04 $ 4.25 100
17.04 $ 4.24 100
17.04 $ 4.25 100
17.04 $ 4.24 100
17.04 $ 4.25 100
In der Zeit zwischen 16:00 - 17:00 Uhr amerikanischer Zeit, lag Steamclls schon über 4,30 US$ ! Nach einer kleinen Abverkaufsphase konnte Stemcells aktuell wieder bis auf 4,28 US Dollar anziehen. ( hatte gerade aktuallisiert )
Also, neute Nacht sollte es wohl eher in Richtung 4,30 als 4,20 US$ gehen.
Morgen werden wir dann schön die 4,52 - 4,90 testen und hoffentlich hoch schließen.
Am Mittwoch ist sie geschaffen, die Basic für die Super-Hype-Ralley, oder für den Absturz.
Mittwoch wäre somit ein nicht schlechter Tag die Gewinne bei Steamcells ein zu streichen. Dabei bleibt nur die große Chance, bei positivem Ausgang der Befragung, das Stemcells erst richtig anfangen wird zu knallen ! Das würde dann heißen, das Stemcells die ganze Woche durch laufen wird und evtl. bis nächste Woche Dienstag anhalten.
Was meint Ihr ? Welches Kurspotenzial sehr Ihr, bei einer richtig heißen Ralley ohne Limit. Da wird in USA gezockt, was nur geht ! Je höher umso besser für uns ! :-)
Morgen geht die Party weiter ! Gruß Euer Byblos
Und sie steigt und steigt ! unaufhaltsam macht sie es !
Heute Abend wird es richtig spannend um Stemcells.
Ich schätze mal, das heute die 5 US$ geknackt werden.
Gruß Byblos
Heute Abend wird es richtig spannend um Stemcells.
Ich schätze mal, das heute die 5 US$ geknackt werden.
Gruß Byblos
Pre-Market
Time (ET) Pre-Market
Price Pre-Market
Share Volume
08.08 $ 4.65 100
08.08 $ 4.67 150
08.08 $ 4.68 450
08.08 $ 4.68 1250
08.08 $ 4.65 850
08.08 $ 4.65 150
08.08 $ 4.65 850
08.08 $ 4.65 5000
08.08 $ 4.65 2500
08.08 $ 4.65 500
08.08 $ 4.65 100
08.08 $ 4.65 1000
08.08 $ 4.65 550
08.08 $ 4.65 150
08.08 $ 4.65 800
08.08 $ 4.65 200
08.08 $ 4.64 1000
08.08 $ 4.65 300
08.08 $ 4.65 200
08.08 $ 4.64 700
08.08 $ 4.64 300
08.08 $ 4.62 400
08.08 $ 4.62 250
08.08 $ 4.62 200
08.07 $ 4.62 130
08.07 $ 4.65 100
08.07 $ 4.62 100
08.07 $ 4.62 300
08.07 $ 4.65 500
08.07 $ 4.65 300
08.07 $ 4.65 2400
08.07 $ 4.65 1000
08.07 $ 4.65 600
08.07 $ 4.65 2000
08.07 $ 4.65 500
08.07 $ 4.65 2000
08.07 $ 4.65 500
08.07 $ 4.65 100
08.07 $ 4.65 100
08.07 $ 4.65 200
08.07 $ 4.65 200
08.07 $ 4.65 600
08.07 $ 4.65 600
08.07 $ 4.65 800
08.07 $ 4.65 4450
08.07 $ 4.65 2000
08.07 $ 4.67 500
08.07 $ 4.67 100
08.07 $ 4.67 200
08.07 $ 4.67 200
Stemcells war aber schon auf über 4,70 US$ gestiegen.
Läßt mal wieder einen fetten Kursanstieg für heute whrscheinlich werden !
Gruß byblos
Time (ET) Pre-Market
Price Pre-Market
Share Volume
08.08 $ 4.65 100
08.08 $ 4.67 150
08.08 $ 4.68 450
08.08 $ 4.68 1250
08.08 $ 4.65 850
08.08 $ 4.65 150
08.08 $ 4.65 850
08.08 $ 4.65 5000
08.08 $ 4.65 2500
08.08 $ 4.65 500
08.08 $ 4.65 100
08.08 $ 4.65 1000
08.08 $ 4.65 550
08.08 $ 4.65 150
08.08 $ 4.65 800
08.08 $ 4.65 200
08.08 $ 4.64 1000
08.08 $ 4.65 300
08.08 $ 4.65 200
08.08 $ 4.64 700
08.08 $ 4.64 300
08.08 $ 4.62 400
08.08 $ 4.62 250
08.08 $ 4.62 200
08.07 $ 4.62 130
08.07 $ 4.65 100
08.07 $ 4.62 100
08.07 $ 4.62 300
08.07 $ 4.65 500
08.07 $ 4.65 300
08.07 $ 4.65 2400
08.07 $ 4.65 1000
08.07 $ 4.65 600
08.07 $ 4.65 2000
08.07 $ 4.65 500
08.07 $ 4.65 2000
08.07 $ 4.65 500
08.07 $ 4.65 100
08.07 $ 4.65 100
08.07 $ 4.65 200
08.07 $ 4.65 200
08.07 $ 4.65 600
08.07 $ 4.65 600
08.07 $ 4.65 800
08.07 $ 4.65 4450
08.07 $ 4.65 2000
08.07 $ 4.67 500
08.07 $ 4.67 100
08.07 $ 4.67 200
08.07 $ 4.67 200
Stemcells war aber schon auf über 4,70 US$ gestiegen.
Läßt mal wieder einen fetten Kursanstieg für heute whrscheinlich werden !
Gruß byblos
Pre-Market
Time (ET) Pre-Market
Price Pre-Market
Share Volume
08.24 $ 4.72 100
08.24 $ 4.73 3315
08.24 $ 4.73 300
08.23 $ 4.74 500
08.23 $ 4.74 100
08.23 $ 4.73 1000
08.23 $ 4.73 600
08.23 $ 4.74 400
08.23 $ 4.74 7200
08.23 $ 4.74 2800
08.23 $ 4.74 1000
08.23 $ 4.74 100
08.23 $ 4.74 100
08.23 $ 4.75 500
Tageshoch bis dato 4,75 US Dollar ! Irre !
Gruß Byblos
Time (ET) Pre-Market
Price Pre-Market
Share Volume
08.24 $ 4.72 100
08.24 $ 4.73 3315
08.24 $ 4.73 300
08.23 $ 4.74 500
08.23 $ 4.74 100
08.23 $ 4.73 1000
08.23 $ 4.73 600
08.23 $ 4.74 400
08.23 $ 4.74 7200
08.23 $ 4.74 2800
08.23 $ 4.74 1000
08.23 $ 4.74 100
08.23 $ 4.74 100
08.23 $ 4.75 500
Tageshoch bis dato 4,75 US Dollar ! Irre !
Gruß Byblos
Gerade ist Stemcells in USA von 4,50 auf 3,66 runter gerauscht.
Schon Minuten später liegt sie wieder über 4 US Dollar.
Grund ?
Bestimmt wurde ein Stimmbezirk ausgezählt and the winner was G. Bush ! So'n shit aber auch.
Mal schauen, was die Aktie macht wenn Kerry einen Erfolg zu verbuchen hat !
Gruß Byblos
P.S.: Jetzt braucht man Nerven wie Stahlseile ! :-)
Schon Minuten später liegt sie wieder über 4 US Dollar.
Grund ?
Bestimmt wurde ein Stimmbezirk ausgezählt and the winner was G. Bush ! So'n shit aber auch.
Mal schauen, was die Aktie macht wenn Kerry einen Erfolg zu verbuchen hat !
Gruß Byblos
P.S.: Jetzt braucht man Nerven wie Stahlseile ! :-)
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem GPC Biotech Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 14 | DANKE USB Warburg !!! Danke,danke,danke..... | Drogo | Rosebud | 25.04.21 02:51 | ||
| 28 | ABIT: +13% auf 55 Euro. Ich Depp habe zu 50 vorhin verkauft... Unverbesserlich! :( o.T. | Dauberus | Dauberus | 25.04.21 00:02 | ||
11 | 103 | Neues aus der Welt der Antikörper und Immunother. | KliP | Heron | 10.09.13 10:53 | |
| 5 | 43 | Biotechnologie? Hör mir bloss auf ! | Parocorp | andyy | 08.12.10 09:27 | |
| 48 | 4.670 | GPC auf dem Weg... | kater123 | techval | 07.10.09 19:30 |
